Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

[Neuromyelitis optica following thymectomy with severe spinal cord atrophy after frequent relapses for 30 years].
Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis.
Pathological mechanisms in progressive multiple sclerosis.
Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
Title: Pharmacokinetics and Pharmacodynamics of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis in the Randomised ADVANCE Study.
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.
Enzon presents pre-clinical data on controlled release of PEGylated interferon-beta-1b and PEGylated anti-TNF-a antibody fragment at the Controlled Release Society annual meeting
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis.
TGN1412: From Discovery to Disaster.
Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in relapsing-Remitting Multiple Sclerosis
Biogen Idec's PLEGRIDY™ (peginterferon beta-1a) approved in the US for the treatment of multiple sclerosis
Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Cladribine
Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolomod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
Rituximab in paediatric onset multiple sclerosis: a case series.
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.
FDA denies Teva Copaxone generic trials petition
Dynamic imaging of individual remyelination profiles in multiple sclerosis.
Mitoxantrone-induced suicidal erythrocyte death.

Pages